Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.

Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.

Methods for treating a bacterial infections, including drug-resistant bacterial infections, of a patient are described. The methods may include applying a non-thermal plasma and a liquid simultaneously to infected tissue of the patient, the liquid comprising at least one antibiotic and/or antiseptic and a penetration enhancing agent; wherein the non-thermal plasma has a frequency between 200 kHz and 600 kHz.

Methods for treating a bacterial infections, including drug-resistant bacterial infections, of a patient are described. The methods may include applying a non-thermal plasma and a liquid simultaneously to infected tissue of the patient, the liquid comprising at least one antibiotic and/or antiseptic and a penetration enhancing agent; wherein the non-thermal plasma has a frequency between 200 kHz and 600 kHz.

The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided. ##STR00001##

The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided. ##STR00001##

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.

The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.

The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.